Esya’s mission is the early, precise, and cost-effective detection of neurodegenerative diseases, using breakthrough cell scanning technology, well before the disease symptoms manifest physically. Today Alzheimer’s Disease (AD) affects one in six of us, and the cost to society is approaching $1 trillion. AD is a costly problem with no single diagnostic, and no personalised treatment plan, and by the time it is diagnosed the disease is already very advanced. This is the problem we hope to address. Our first product will be for Alzheimer’s Disease, to provide a 360 perspective with a first in class diagnostic to chemically profile Alzheimer’s disease in its earliest stage, create a personalised treatment plan based on ranked drug effectiveness for any given patient, and tracking the progression of the disease.